Nonselective beta‐blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States

Summary Background Previous studies have demonstrated an association between nonselective beta‐blockers (NSBBs) and lower risk of hepatocellular carcinoma (HCC) in cirrhosis. However, there has been no population‐based study investigating the risk of HCC among cirrhotic patients treated using carved...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2021-08, Vol.54 (4), p.481-492
Main Authors: Wijarnpreecha, Karn, Li, Fang, Xiang, Yang, Xu, Xun, Zhu, Cong, Maroufy, Vahed, Wang, Qing, Tao, Wei, Dang, Yifang, Pham, Huy Anh, Zhou, Yujia, Li, Jianfu, Zhang, Xinyuan, Xu, Hua, Taner, C. Burcin, Yang, Liu, Tao, Cui
Format: Article
Language:English
Subjects:
Beta blockers
Cirrhosis
Hepatocellular carcinoma
Liver cancer
Liver cirrhosis
Population studies
Propranolol
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Previous studies have demonstrated an association between nonselective beta‐blockers (NSBBs) and lower risk of hepatocellular carcinoma (HCC) in cirrhosis. However, there has been no population‐based study investigating the risk of HCC among cirrhotic patients treated using carvedilol. Aims To determine the risk of HCC among cirrhotic patients with NSBBs including carvedilol. Methods This retrospective cohort study utilised the Cerner Health Facts database in the United States from 2000 to 2017. Kaplan‐Meier estimate, Cox proportional hazards regression, and propensity score matching (PSM) were used to test the HCC risk among the carvedilol, nadolol, and propranolol groups compared with no beta‐blocker group. Results The final cohort comprised 107 428 eligible patients. The 100‐month cumulative HCC incidence of NSBBs was significantly lower than the no beta‐blocker group (carvedilol (11.24%) vs no beta‐blocker (15.69%), nadolol (27.55%) vs no beta‐blocker (32.11%), and propranolol (26.17%) vs no beta‐blocker (28.84%) (P values 
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.16490